Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study
Hamrahian et al. • 2025 • AACE 2025 Congress
© 2024 Corcept Therapeutics, Incorporated
Characterization of Patients With Difficult-to-Control Type 2 Diabetes and a Post–Dexamethasone Suppression Test Cortisol of 1.2–1.8 μg/dL: Findings From a Large Prospective Study
Busch et al. • 2025 • AACE 2025 Congress
A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism
Hannoush et al. • 2025 • AACE 2025 Congress
Clinical Learnings Based on a Case Series: Considerations for Identifying and Treating Hypercortisolism in Patients with Diabetes
Lucci et al. • 2025 • AACE
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Pivonello et al. • 2025 • ESPE, ESE
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results
Badiu et al. • 2025 • ESPE, ESE
Relacorilant Improved Blood Pressure and Maintained Other Cardiometabolic Improvements in Long-term Study in Patients With Endogenous Hypercortisolism (Cushing Syndrome)
Dr. Richard J. Auchus • 2024 • WCIRDC
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results
Araque et al. • 2024 • WCIRDC
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Araque et al. • 2024 • WCIRDC
Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: Results from CATALYST
Fonseca et al. • 2024 • WCIRDC